Physician profile
Mark Mazak
NPI 1285748897
$21,033.23
in general payments reported to CMS, 2019-2025
26 companies · $2,125 in 2025
The $2,125 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $5,034 · 2022: $4,246 · 2023: $7,378 · 2024: $2,249 · 2025: $2,125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,255 · Food and Beverage: $4,211 · Consulting Fee: $750 · Travel and Lodging: $281 · Education: $256.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,255.00 |
| Food and Beverage | $4,210.98 |
| Consulting Fee | $750.00 |
| Travel and Lodging | $280.86 |
| Education | $255.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $15,253.97 | 2021-2024 | Ilumya, Winlevi |
| Janssen Biotech, INC. | $1,144.02 | 2022-2025 | Tremfya, Remicade, Simponi |
| Journey Medical Corporation | $763.11 | 2022-2025 | |
| Abbvie INC. | $621.60 | 2021-2025 | |
| Dermavant Sciences, INC. | $609.58 | 2023-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $404.03 | 2023-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $364.18 | 2021-2025 | Sotyktu |
| Genzyme Corporation | $248.26 | 2022-2025 | |
| Amgen INC. | $189.77 | 2023-2025 | Otezla, Otezla, Enbrel |
| Mayne Pharma Commercial LLC | $181.21 | 2022-2025 | |
| Ucb, INC. | $161.49 | 2025 | Bimzelx |
| Epi Health, LLC | $150.99 | 2022 | |
| Lilly USA, LLC | $137.19 | 2023-2025 | Olumiant, Taltz, Ebglyss |
| Novartis Pharmaceuticals Corporation | $136.23 | 2021-2025 | |
| Galderma Laboratories, L.P. | $129.43 | 2025 | Nemluvio |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $89.01 | 2025 | Vtama |
| Sanofi-Aventis U.S. LLC | $79.99 | 2022 | |
| Leo Pharma INC. | $79.76 | 2023-2024 | Adbry |
| Vyne Pharmaceuticals INC. | $53.00 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $50.69 | 2023-2025 | Cabtreo, Arazlo |
| Incyte Corporation | $50.16 | 2023-2024 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $36.63 | 2024-2025 | Libtayo, Dupixent |
| Organogenesis INC. | $35.46 | 2024-2025 | Cygnus Dual |
| Pfizer INC. | $34.40 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.58 | 2023 | Cyltezo |
| Verrica Pharmaceuticals INC. | $14.49 | 2023 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Mazak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.